Zentalis Pharmaceuticals, Inc. financial data

Symbol
ZNTL on Nasdaq
Industry
Pharmaceutical Preparations
Location
1359 Broadway, Suite 801, New York, New York
Fiscal year end
December 31
Former names
Zentalis Pharmaceuticals, LLC (to 4/6/2020), Zeno Pharma, LLC (to 9/5/2019)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 891 % +8.99%
Debt-to-equity 21.8 % -7.15%
Return On Equity -46.1 % +17.8%
Return On Assets -37.8 % +16.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71 M shares +19.5%
Common Stock, Shares, Outstanding 71 M shares +19.5%
Entity Public Float 1.56 B USD +20%
Common Stock, Value, Issued 70 K USD +18.6%
Weighted Average Number of Shares Outstanding, Basic 70.9 M shares +19.6%
Weighted Average Number of Shares Outstanding, Diluted 71.2 M shares +20.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 40.6 M USD
Research and Development Expense 191 M USD +8.78%
General and Administrative Expense 63.7 M USD +7.72%
Operating Income (Loss) -259 M USD -10.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -293 M USD -23.3%
Income Tax Expense (Benefit) -566 K USD -43.7%
Net Income (Loss) Attributable to Parent -219 M USD +9.15%
Earnings Per Share, Basic -3.26 USD/shares +23.1%
Earnings Per Share, Diluted -3.26 USD/shares +23.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.6 M USD +3.68%
Assets, Current 504 M USD +22.8%
Property, Plant and Equipment, Net 5.68 M USD -17.5%
Operating Lease, Right-of-Use Asset 34.7 M USD -7.34%
Goodwill 3.74 M USD 0%
Assets 557 M USD +13.9%
Accounts Payable, Current 10.5 M USD -18.1%
Employee-related Liabilities, Current 6.63 M USD -3.68%
Accrued Liabilities, Current 44.3 M USD +1.74%
Liabilities, Current 54.8 M USD -2.77%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 42.6 M USD -4.81%
Other Liabilities, Noncurrent 1.29 M USD -27.8%
Liabilities 98.7 M USD -4.79%
Accumulated Other Comprehensive Income (Loss), Net of Tax 773 K USD
Retained Earnings (Accumulated Deficit) -878 M USD -33.2%
Stockholders' Equity Attributable to Parent 459 M USD +19%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 459 M USD +19%
Liabilities and Equity 557 M USD +13.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52 M USD -5.46%
Net Cash Provided by (Used in) Financing Activities 237 M USD -9.09%
Net Cash Provided by (Used in) Investing Activities 61.5 M USD +46.1%
Common Stock, Shares Authorized 250 M shares 0%
Common Stock, Shares, Issued 71 M shares +19.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.58 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 40.3 M USD +3.57%
Deferred Tax Assets, Valuation Allowance 219 M USD +36.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 230 M USD +31.2%
Operating Lease, Liability 45.4 M USD -3.54%
Payments to Acquire Property, Plant, and Equipment 40 K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -218 M USD +9.49%
Lessee, Operating Lease, Liability, to be Paid 66.1 M USD -7.93%
Property, Plant and Equipment, Gross 9.08 M USD -8.91%
Operating Lease, Liability, Current 2.74 M USD +21.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.49 M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 7 M USD +7.96%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) -891 K USD -14.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 20.7 M USD -16.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.61 M USD +4.51%
Deferred Tax Assets, Operating Loss Carryforwards 96.7 M USD +1.35%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) -891 K USD -30.5%
Current Income Tax Expense (Benefit) 290 K USD -6.15%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 4.21 M USD -1.93%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.76 M USD +4.15%
Operating Lease, Payments 6.4 M USD +156%
Additional Paid in Capital 1.34 B USD +27.8%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 41 K USD +273%
Current Federal Tax Expense (Benefit) 0 USD
Depreciation, Depletion and Amortization 1.35 M USD -6.17%
Deferred Tax Assets, Net of Valuation Allowance 10.4 M USD -26.6%
Share-based Payment Arrangement, Expense 53.9 M USD +6.93%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%